65,437 trials
Metastatic Castrate-resistant Prostate Cancer · Adenocarcinoma, Prostate
Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 0; 0; 0; 0 Participants
Gastrointestinal Stromal Tumors
Primary: Progression-Free Survival (PFS) — 27.6; 4.1 Weeks — p=<0.0001
Sedentary Behavior · Cardiovascular Risk Factor · Mental Stress
Primary: Mean Change in Brachial-femoral Pulse Wave Velocity (bfPWV) — -0.26; 0.22 m/s
Preoperative Skin Preparation
Primary: Bacterial Count at 10 Minutes Post Application — 3.55; 3.61; 3.66; 1.19 log10 CFU/cm^2
Obstructive Sleep Apnea
Primary: Difference Between Optimal Pressure (cm H2O) Derived From APAP run-in Period Versus Result of CPAP Titration Study — 7.3; 9.4 cmH2O
Respiratory Distress Syndrome
Primary: Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS) — 31; 32; 31 Participants — p=0.363
Enterotoxigenic Escherichia Coli Infection · Diarrhea
Primary: Percentage of Subjects With Moderate to Severe Diarrhea — 7; 11 Participants
Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Overall Response Rate (ORR) in Patients With Metastatic HER2 Negative Breast Cancer Treated With Durvalumab in Combination With Tremelimumab — 4 participants
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
Phantom Limb Pain
Primary: Pain as Measured by the Visual Analog Scale — -1.4 units on a scale
Oligometastases
Primary: Percentage of Participants With Freedom From Local Progression (FFLP) — 78.4 percentage of participants
Alkaptonuria
Primary: Homogentisic Acid Excretion — 1425.9; 113.1; 34.0 uM
Waldenström Macroglobulinemia
Primary: Overall Response Rate — 3 Participants
Acute Pancreatitis
Primary: Systemic Inflammatory Response Syndrome (SIRS) Score — -0.96; -1 score on a scale — p=0.87
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 9; 10; 15; 17 participants